Covalence has a wealth of health economic modeling expertise, spanning numerous therapy areas, modeling objectives, model structures, and technology platforms.
Furthermore, in the reimbursement context, Covalence has consistently delivered models that have resulted in successful reimbursement of the health technology of interest, including models that have formed the basis of submissions to the National Institute for Health and Care Excellence (NICE) and the Canadian Agency for Drugs and Technologies in Health (CADTH).
The Covalence team has performed dozens of systematic literature reviews, including reviews that have formed the basis of widely-cited peer-reviewed manuscripts and reimbursement submissions.
Since systematic literature reviews often form the bedrock of evidence synthesis efforts such as network meta-analyses and evidence generation efforts such as cost-utility modeling, Covalence takes the process very seriously. So seriously, in fact, that we've developed our own in-house software for conducting systematic literature reviews: Sourcerer. Sourcerer allows Covalence to rapidly screen large volumes of literature and provide bibliographies and literature review outputs in a consistent format.
Covalence has extensive experience running meta-analyses, including everything from pooling of data from multiple trials of the same interventions, through indirect treatment comparisons, to complex network meta-analyses.
In the interests of ensuring that meta-analyses are conducted and reported in accordance with best practice guidelines from ISPOR and NICE, Covalence sponsors the BUGSnet project and works in close collaboration with the University of Waterloo to steward its ongoing development.
Medical writing and value communications are among the core services offered by Covalence. This includes the preparation of systematic literature reviews, global value dossiers and value messages to support reimbursement as well as landscape reviews, manuscripts, posters, slide kits and medical education resources.
Attention to detail and a desire to produce the highest quality deliverables possible is at the cornerstone of everything we do. We work closely with clients to ensure that each project is tailored to meet the specific needs of the market and therapy area in question ensuring that all deliverables are customized and underline the nuances and value of each individual intervention.
The Covalence team have a wealth of experience in medical writing across a broad range of therapy areas with particular expertise in diabetes, oncology and virology. Examples of recent manuscripts published by the Covalence team can be found here.
Data underpins everything we do at Covalence and, whether it's clinical or commercial, it's important to able to quickly gain insights into key signals and messages from the data.
So whether it's one of our off-the-shelf offerings such as our Secondary Care Medicines Data (SCMD) Dashboard (right) or a bespoke dashboard to unearth themes or trends from your own datasets, we are well equipped to deliver elegant and incisive dashboards using an array of modern, secure, and efficient technologies, including Shiny and Angular.
For enquiries pertaining to Covalence's SCMD Dashboard, please contact firstname.lastname@example.org.
Richard is a Health Economist and Director at Covalence.
Having graduated with a first-class MSci in Natural Sciences from the University of Cambridge in 2007, he has since worked as a health economist for over 15 years. He has developed models, formulated analysis plans, and managed health technology assessment submissions that have contributed to successful reimbursement decisions at the SMC, NICE, AMCP and CADTH, and has published over 70 peer-reviewed publications and dozens of congress and conference presentations.
Johannes is a Health Economist at Covalence.
Johannes graduated with a BA in Political Science and Economics from the University of Munich in 2013. He went on to complete an MSc in Demography & Health at the London School of Hygiene and Tropical Medicine in 2015 and an MPH from the University of Munich in 2016. He has since worked on health economic evaluations of public health interventions and health technology assessments, including for biosimilar infliximab in Switzerland, at the Zurich University of Applied Sciences (Switzerland) and on autonomic dysfunction in heart failure at the University of Mainz (Germany).
Jayne is a Senior Consultant at Covalence, specialising in medical writing, evidence synthesis, and value communication.
Jayne graduated with a BSc in Biology from the University of St Andrews in 2002. She went on to complete a DPhil in biophysics at Oxford University in collaboration with the National Institute for Medical Research, London, UK and the National Heart Lung and Blood Institute, Bethesda, MD, USA. Since then, she has gained over 15 years of experience in medical writing and value communications, and has coauthored over 30 publications in the peer-reviewed literature.
Waqas is a Data Scientist at Covalence.
Waqas graduated with a first-class MPharm from University College London in 2017 and went on to obtain a distinction in his MSc in Health Economics at the University of York in 2020. He subsequently joined PHMR Ltd in London as a health economist where he worked on several patient-reported outcomes projects. Waqas joined Covalence as a Data Scientist in 2022 where he continues to work on a variety of health economic modeling, evidence synthesis and data visualisation projects across a wide range of therapy areas.
Neesha is a Senior Evidence Synthesis Consultant at Covalence.
Neesha graduated with a BSc in Biomedical Science from the University of Kent in 2015 and went on to complete an MSc in epidemiology at Imperial College London. She subsequently worked as a Research Assistant at Imperial where she worked on a continuously-updated systematic literature review funded by the World Cancer Research Fund International on the role of diet, nutritional status, anthropometric characteristics and physical activity in cancer prevention and prognosis. Neesha joined Covalence in 2022 where she continues to work on epidemiological research and novel evidence synthesis projects.
Silvia is a Senior Consultant at Covalence, specialising in evidence review and synthesis.
Silvia obtained a PhD in chemistry in 2004 from the University of Venice, Italy, in collaboration with the University of Liverpool, UK. She has since held a variety of roles in academia and consultancy, including 9 years working in NICE Clinical Guideline development. Silvia joined Covalence in 2023 where she works on a variety of health evidence review synthesis and value communication projects across a broad range of disease areas.
Tray is a Principal at Covalence.
Tray previously held senior leadership and technical modelling roles in consulting and academia, and joined Covalence as Principal in 2024. Prior to joining Covalence, Tray was Director of Health Economics at HEOR Ltd where he provided strategic consulting and led the development of models in a wide range of disease areas including cardiovascular, oncology, infectious diseases and autoimmune indications. His experience includes building global models for later country-specific adaptations as well as models for HTA submissions to NICE, interpreting both real-world and clinical trial data to produce complex cost-effectiveness models and conducting value of information analyses. Tray has also developed and advised on early-stage models for strategic planning and budget impact for both global and country-specific settings, including in the US and UK.
Project-related or other enquiries can be sent to email@example.com.
+44 20 8638 6525
+1 (202) 697-9435
+41 44 585 19 85
Covalence is headquartered at Rivers Lodge, West Common, Harpenden, AL5 2JD.